Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is traditionally considered as primarily affecting the right ventricle. Mutations in genes encoding desmosomal proteins account for 40-60% of cases. Genotype-phenotype correlations are scant and mostly non gene-specific. Accordingly, we assessed the genotype-phenotype correlation for desmoplakin (DSP) missense and non-missense mutations causing ARVC.

Methods And Results: We analyzed 27 ARVC patients carrying a missense or a non-missense DSP mutation, with complete clinical assessment. The two groups were compared for clinical parameters, basic demographics such as sex, age at diagnosis, age at disease onset, as well as prevalence of symptoms and arrhythmic events. Missense DSP variants were present in 10 patients and non-missense in 17. Mean age at diagnosis and at first arrhythmic event did not differ between the two groups. Also the prevalence of symptoms, either major (60% vs 59%, p=1) or all (80% vs 88%, p=0.61), did not differ. By contrast, left ventricular (LV) dysfunction was significantly more prevalent among patients with non-missense mutations (76.5% vs 10%, p=0.001), who were also much more likely to have a structural LV involvement by Cardiac Magnetic Resonance (CMR) (92% vs 22%, p=0.001).

Conclusions: For ARVC patients, both missense and non-missense DSP mutations carry a high arrhythmic risk. Non-missense mutations are specifically associated with left-dominant forms. The presence of DSP non-missense mutations should alert to the likely development of LV dysfunction. These findings highlight the clinical relevance of genetic testing even after the clinical diagnosis of ARVC and the growing clinical impact of genetics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2017.05.018DOI Listing

Publication Analysis

Top Keywords

non-missense mutations
20
missense non-missense
16
non-missense
8
arrhythmogenic ventricular
8
ventricular cardiomyopathy
8
genotype-phenotype correlation
8
arvc patients
8
non-missense dsp
8
age diagnosis
8
prevalence symptoms
8

Similar Publications

[Genetic and clinical characteristics of 26 cases with glycogen storage disease type Ⅲ].

Zhonghua Gan Zang Bing Za Zhi

November 2024

The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, Shanghai201102, China.

Article Synopsis
  • The study analyzed the genetic and clinical profiles of 26 patients with glycogen storage disease type III (GSD III), focusing on the effects of different genetic mutations in the AGL gene.
  • It found that the most common symptoms included elevated liver enzymes, hepatomegaly, and fasting hypoglycemia, and that liver biopsies revealed significant fibrosis in 83.3% of cases.
  • After treatment with uncooked cornstarch for over a year, patients showed improvements in growth, liver size, and metabolic markers, although a subset of cases still experienced clinical issues.
View Article and Find Full Text PDF

[Analysis of the regional distribution differences of common variations of the MMACHC gene in cblC methylmalonic acidemia patients].

Zhonghua Er Ke Za Zhi

November 2024

Department of Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

To analyze regional differences in MMACHC gene variations among patients with cblC-type methylmalonic acidemia (MMA) in China and to explore the relationship between these variations and neonatal screening, biochemical markers and prognosis. Retrospective case summary. Clinical and laboratory data, including general condition, biochemical markers and genetic analysis, were collected from 1 859 cblC MMA patients from 2005 to 2023.

View Article and Find Full Text PDF

How We Treat Hemolytic Anemia Due to Pyruvate Kinase Deficiency.

Hematol Rep

August 2024

Department of Hematology and Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA.

Article Synopsis
  • Pyruvate kinase (PK) deficiency is an inherited condition causing chronic hemolytic anemia, with symptoms like fatigue, jaundice, and gallstones, typically managed with transfusions and other supportive therapies.
  • Mitapivat is a newly approved oral medication that activates RBC PK enzymes and has shown positive results in some patients by improving hemoglobin levels and reducing transfusion needs, though not all respond to it.
  • The response to mitapivat varies based on individual genetic factors, suggesting that both clinical symptoms and genetic background should be considered before starting treatment.
View Article and Find Full Text PDF

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms.

Cell Commun Signal

August 2024

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

TP53 mutation (TP53-mut) correlates with inferior survival in many cancers, whereas its prognostic role in diffuse large B-cell lymphoma (DLBCL) is still in controversy. Therefore, more precise risk stratification needs to be further explored for TP53-mut DLBCL patients. A set of 2637 DLBCL cases from multiple cohorts, was enrolled in our analysis.

View Article and Find Full Text PDF

Arrhythmic risk stratification in patients with Lamin A/C gene (LMNA)-related cardiomyopathy influences clinical decisions. An implantable cardioverter defibrillator (ICD) should be considered in patients with an estimated 5-year risk of malignant ventricular arrhythmia (MVA) of ≥10%. The risk prediction score for MVA includes non-missense LMNA mutations, despite their role as an established risk factor for sudden cardiac death (SCD) has been questioned in several studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!